HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening

被引:17
|
作者
Kreuger, Aukje L. [1 ,2 ]
Makelburg, Anja B. U. [3 ,4 ]
Somers, Judith A. E. [3 ,5 ]
Tomson, Bert [3 ]
van de Watering, Leo M. G. [3 ]
van der Bom, Johanna G. [1 ,2 ]
van Kraaij, Marian G. J. [1 ,3 ,6 ]
Weller, Claudia M. [3 ]
机构
[1] Sanquin Res, Ctr Clin Transfus Res, Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[3] Sanquin Blood Bank, Unit Transfus Med, Amsterdam, Netherlands
[4] Sanquin Blood Bank, Unit Donor Affairs, Amsterdam, Netherlands
[5] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands
[6] Erasmus MC Daniel Den Hoed Canc Ctr, Dept Hematol, Rotterdam, Netherlands
关键词
THROMBOCYTOPENIA; MANAGEMENT; INCREMENTS;
D O I
10.1111/trf.15530
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Recipients of platelet transfusions with 1-hour corrected count increments (1hCCIs) of 7.5 or less on two subsequent platelet transfusions with random platelets may benefit from human leukocyte antigen (HLA)-matched platelet concentrates. We aimed to quantify the efficacy of HLA-matched platelets concentrates expressed in 1hCCIs. METHODS We performed a cohort study among consecutive refractory patients who received HLA-matched platelet concentrates in the Netherlands between 1994 and 2017. We performed mixed-model linear regression comparing 1hCCIs after HLA split-antigen-matched transfusions with 1hCCIs after HLA-mismatched transfusions, adjusted for within-patient correlations. A donor-to-patient match was categorized as a split-match if all donor HLA-A and -B antigens were present in the patient as well; that is, donor and patient were HLA identical or compatible. Subgroup analyses were performed for patients with positive or negative HLA antibody screens. Finally, the additional effect of ABO mismatches on 1hCCIs was investigated. RESULTS The 1hCCI after an HLA-matched transfusion was 14.09 (95% reference interval, 1.13-29.89). This was 1.94 (95% confidence interval [CI], 0.74-3.15) higher than 1hCCI after HLA-mismatched transfusions. In patients with negative HLA antibody screening tests, HLA matching did not affect 1hCCIs. Conditional on HLA matching, 1hCCIs decreased by 3.70 (95% CI, -5.22 to -2.18) with major ABO mismatches. CONCLUSION Matched platelet concentrates yielded maximal 1hCCIs, whereas mismatched transfusions still resulted in adequate increments. There is no indication for HLA-matched platelets in patients with negative antibody screens.
引用
收藏
页码:3303 / 3307
页数:5
相关论文
共 50 条
  • [31] HLA ALLOIMMUNIZATION WITH LEUKOCYTE CONCENTRATES FROM HLA-MATCHED AND HLA-NON-MATCHED DONORS IN PATIENTS WITH HUNTERS SYNDROME
    KAKAIYA, RM
    GREENSTEIN, R
    PISCIOTTO, P
    SLOCUM, SK
    ROSEN, D
    CABLE, RG
    MORSE, EE
    GAINEY, A
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1985, 15 (05): : 435 - 440
  • [32] COMPARISON OF HLA ANTIBODY IDENTIFICATION METHODS FOR THE SELECTION OF PLATELET PRODUCTS FOR HLA-MEDIATED PLATELET REFRACTORY PATIENTS
    Pedini, Pascal
    Hubert, Lucas
    Thorrignac, Thomas
    Denhadji, Yasmina
    Basire, Agnes
    Chiaroni, Jacques
    Ladaique, Patrick
    Picard, Christophe
    HLA, 2021, 97 (04) : 334 - 335
  • [33] Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patients
    Pedini, Pascal
    Hubert, Lucas
    Baudey, Jean-Baptiste
    Etienne, Jean-Michel
    Basire, Agnes
    Vey, Norbert
    Chiaroni, Jacques
    Chabrieres, Corinne
    Ladaique, Patrick
    Picard, Christophe
    HLA, 2024, 103 (01)
  • [34] HLA-MATCHED PLATELET TRANSFUSION THERAPY OF SEVERE APLASTIC-ANEMIA
    TOSATO, G
    APPLEBAUM, FR
    DEISSEROTH, AB
    BLOOD, 1978, 52 (04) : 846 - 854
  • [35] HLA-MATCHED PLATELET TRANSFUSION THERAPY OF SEVERE APLASTIC-ANEMIA
    TOSATO, G
    APPELBAUM, FR
    DEISSEROTH, AB
    BLOOD, 1979, 54 (01) : 293 - 293
  • [36] HLA-MATCHED PLATELET TRANSFUSION RESCUED THE LIFE OF A CHILD WITH SEVERE THROMBOCYTOPENIA
    Dada, Ashraf
    Bokhari, Ahmad
    Alsuraihi, Osma
    Al Baz, Nabeela
    Al-Johani, Mohammed
    HUMAN IMMUNOLOGY, 2018, 79 : 74 - 74
  • [37] AN EVALUATION OF CROSS-MATCHING, HLA, AND ABO MATCHING FOR PLATELET TRANSFUSIONS TO REFRACTORY PATIENTS
    HEAL, JM
    BLUMBERG, N
    MASEL, D
    BLOOD, 1987, 70 (01) : 23 - 30
  • [38] Crossmatched (XMPs) and HLA-matched (HLA-MPs) apheresis platelets may benefit refractory patients without alloantilbodies.
    Mair, DC
    Bester, JU
    Eastlund, T
    TRANSFUSION, 2002, 42 (09) : 102S - 103S
  • [39] A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions
    Sintnicolaas, K
    Lowenberg, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) : 1005 - 1010
  • [40] RED-CELLS, HLA AND PLATELET ANTIBODY-FORMATION IN PATIENTS WITH MULTIPLE TRANSFUSIONS
    CHOW, MP
    HU, HY
    LYOU, JY
    LIN, JS
    YUNG, CH
    LEE, A
    LEE, TD
    ACTA HAEMATOLOGICA, 1994, 92 (02) : 57 - 60